ORIC Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGORIC Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 64), indicating performance broadly in line with the market. Earnings growth of 19% provides fundamental context to the price action. However, price is extended 21% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.23 | +17.90% | ABOVE |
| 50 SMA | $8.96 | +21.47% | ABOVE |
| 100 SMA | $10.15 | +7.16% | ABOVE |
| 150 SMA | $10.11 | +7.63% | ABOVE |
| 200 SMA | $10.67 | +1.96% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ORIC in an uptrend right now?
ORIC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ORIC overbought or oversold?
ORIC's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is ORIC outperforming the market?
ORIC has a Relative Strength (RS) Rating of 64 out of 99. ORIC is performing about average compared to the market.
Where is ORIC in its 52-week range?
ORIC is trading at $10.88, which is 73% of its 52-week high ($14.93) and 47% above its 52-week low ($7.23).
How volatile is ORIC?
ORIC has a Beta of 1.20 and 52-week volatility of 81%. It's more volatile than the S&P 500 - expect bigger swings.